Although molecular-targeted drugs, such as the tyrosine kinase inhibitors (TKI) and inhibitors of the mammalian target of rapamycin (mTOR), are currently administered for the treatment of metastatic ccRCC, the effects of these drugs are limited and not curative [4]. Here, MTOR is linked to nonpapillary renal cell carcinoma.